Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CPT2 | P23786 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HMGCR | P04035 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667038 | 0.93 | ADRA2A (0.30) | ADRA1A | |
| SCHEMBL4254119 | 0.85 | TDP1 (0.46) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL7841654 | 0.75 | GAA (0.46) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL4334241 | 0.75 | MGAM (0.36) | ADRA1ATSHR | |
| SCHEMBL1506857 | 0.74 | NAAA (0.56) | FFAR1CPT2TDP1TSHR | |
| SCHEMBL1506826 | 0.74 | NAAA (0.56) | FFAR1CPT2TDP1TSHR | |
| SCHEMBL1506852 | 0.74 | NAAA (0.56) | FFAR1CPT2TDP1TSHR | |
| SCHEMBL1506885 | 0.74 | NAAA (0.56) | FFAR1CPT2TDP1TSHR | |
| SCHEMBL12055333 | 0.74 | TDP1 (0.37) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL1506836 | 0.74 | NAAA (0.56) | FFAR1CPT2TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3796900-B1 | TRITERPENE AMINE DERIVATIVES | DFH THERAPEUTICS (US) | 2026-04-08 | — | — | EP | disclosed |
| US-11236122-B2 | Triterpene amine derivatives | DFH THERAPEUTICS (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-08-19 | — | — | US | disclosed |
| EP-3796900-A1 | TRITERPENE AMINE DERIVATIVES | DFH Therapeutics (US) | 2021-03-31 | — | — | EP | disclosed |
| US-20170096446-A1 | Extended Triterpene Derivatives | MYREXIS, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-9505800-B2 | Extended triterpene derivatives | MYREXIS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20120046291-A1 | Extended Triterpene Derivatives | MYREXIS, INC. | 2012-02-23 | — | — | US | disclosed |
| WO-2008057420-A2 | EXTENDED TRITERPENE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | BET1, PGGT1B, NFATC1 | KDM4E 1661/4885FFAR1 3651/4885CPT2 2221/4885 |
| US-20170096446-A1 | Extended Triterpene Derivatives | BET1, PGGT1B, TMPO | KDM4E 2853/4885FFAR1 3689/4885CPT2 1593/4885 |
| US-20120046291-A1 | Extended Triterpene Derivatives | BET1, PGGT1B, TMPO | KDM4E 2853/4885FFAR1 3689/4885CPT2 1593/4885 |
| US-11236122-B2 | Triterpene amine derivatives | BET1, PGGT1B, NFATC1 | KDM4E 1661/4885FFAR1 3651/4885CPT2 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.